Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 65Neoplasms 50Colorectal Neoplasms 49Prostatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 34Pancreatic Neoplasms 27Leukemia, Myeloid, Acute 23Multiple Myeloma 21Recurrence 17Carcinoma, Hepatocellular 17Uterine Cervical Neoplasms 16Ovarian Neoplasms 15Neoplasm Metastasis 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Triple Negative Breast Neoplasms 12Stomach Neoplasms 12Melanoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Glioblastoma 11Endometrial Neoplasms 11Rectal Neoplasms 10Carcinoma, Renal Cell 10Brain Neoplasms 10Advanced Solid Tumors 10Lymphoma, B-Cell 9Disease 9Colonic Neoplasms 9Esophageal Neoplasms 8

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ALK Positive Non-small Cell Lung Cancer × 30 days × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡